1.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,...
by Zhou, Caicun, Prof
The lancet oncology, 2011, Vol.12 (8), p.735-742
2.
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, rand...
by Sun, Ying, Prof
The lancet oncology, 2016, Vol.17 (11), p.1509-1520
3.
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multi...
by Chen, Lei, MD
The lancet oncology, 2012, Vol.13 (2), p.163-171
4.
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis
by Zhang, Jia-Xing, MD
The lancet oncology, 2013, Vol.14 (13), p.1295-1306
Filter electronic articles 4 Hits
Remove Filters
- Journal Title
- The Lancet Oncology
- Middle Aged (4)
- Male
- Female (4)
- Humans (4)
- Hematology, Oncology And Palliat... (4)
- Life Sciences & Biomedicine (4)
- Medical Colleges (3)
- Neoplasm Staging (3)
- Disease-Free Survival (3)
- Aged (3)
- China (3)
- Chemotherapy (3)
- Carcinoma (2)
- Care And Treatment (2)
- Analysis (2)
- Adult (2)
- Antineoplastic Combined Chemothe... (2)
- less ...